Atara Biotherapeutics - Company Information

Atara biotherapeutics inc., is a leading allogeneic t-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  with our lead program receiving marketing authorization in europe, atara is the most advanced allogeneic t-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. our platform leverages the unique biology of ebv t cells and has the capability to treat a wide range of ebv-associated diseases, or other serious diseases through incorporation of engineered cars (chimeric antigen receptors) or tcrs (t-cell receptors). atara is applying this one platform, which does not require tcr or hla gene editing, to create a robust pipeline including: tab-cel for epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) and other ebv-driven diseases; ata188, a t-cell immunotherapy targeting ebv antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor t-cell (car-t) immunotherapies for both solid tumors and hematologic malignancies.

Biotechnology